Prinzmetal Angina Therapeutics Market
Market Insights on Prinzmetal Angina Therapeutics covering sales outlook, demand forecast & up-to-date key trends
Prinzmetal Angina Therapeutics Market by Disease Type, Drug Class, Distribution Channel & Region – Forecast 2023–2033
Prinzmetal Angina Therapeutics Market Snapshot (2023-2033)
The global prinzmetal angina therapeutics market is expected to surpass an impressive valuation of US$ 10.7 Billion in 2023, and is projected to reach US$ 17.2 Billion by 2033, trailing a CAGR of 4.85%. A major driving factor for the is the rise in the patient population suffering from cardiac disorders such as coronary heart disease. For instance, as per the data published by the World Health Organization, in December 2020, ischemic heart disease was the world's leading cause of death, accounting for around 16 percent of all deaths. This disease has shown the highest increase in deaths since 2000, increasing by more than 2 million to 8.9 million deaths in 2020.
Stroke and chronic obstructive pulmonary disease (COPD) are the second and third largest causes of death, accounting for around 11% and 6% of all deaths, respectively. In addition, an article titled "Angina: contemporary diagnosis and management" published in PubMed Central, in February 2020, stated that Ischemic heart disease (IHD) continues to be the largest cause of death and lost life years in adults, particularly among women under the age of 55. Angina pectoris is a typical clinical manifestation of IHD and is chest discomfort caused by a heart attack. Therefore, the rising number of patients suffering from IHD is likely to impel the market growth for angina pectoris drugs over the forecast period, thereby driving the market growth. However, growing adoption of minimally invasive surgeries and side effects associated with certain drug classes are some of the factors that may restrain market's growth in the coming years.
For instance, as per a study titled "Long COVID-19 and microvascular disease-related angina" published in Sociedad Española de Cardiología, in November 2021, after meticulous evaluation and exclusion of other illnesses, the researchers found that 27.1% of the patients evaluated in a long COVID-19 unit had chest pain, some of which was suggestive of angina. A total of 186 patients were enrolled in the trial, 51 (27%) of whom reported ongoing chest pain after being examined in the long COVID-19 unit. Thus, such studies highlighted the need for drugs to manage angina pectoris in COVID-19 patients, ultimately boosting the demand for targeted drugs. Therefore, the rising number of COVID-19 patients with cardiological complications is likely to boost the market's growth over the forecast period.
Furthermore, factors driving the market growth include the rising burden of lifestyle diseases, especially cardiac disorders; technological advancements towards personalized cardiovascular medicine; and the advancement in novel drug delivery systems.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 10.7 Billion |
|
Anticipated Forecast Value (2033) |
US$ 17.2 Billion |
|
Projected Growth Rate (2023-2033) |
CAGR 4.85% |
Let us know your requirement to get
100% FREE customization
2018-2022 Prinzmetal Angina Therapeutics Demand Analysis vs. Forecast 2023-2033
The prinzmetal angina therapeutics market was valued at US$ 9.08 Billion in 2018 while growing at a CAGR of 2.65% during the historical period. With the advent of Novel target drugs and therapies gaining traction like Factor Xa Inhibitors, monoclonal antibodies, and gene therapy are boosting the therapeutics market.
Considering these factors, the Prinzmetal Angina therapeutics market is projected to reach US$ 17.2 Billion, while exhibiting CAGR of 4.85% during the forecast period.
Which are Some Prominent Drivers of the Prinzmetal Angina therapeutics Market?
Emerging therapies to propel market growth
New therapies entering the market will be the main drivers of growth, with one gene-based therapy, Generx (Ad5FGF-4), and two cell-therapy treatments, CLBS16 and CLBS14 anticipated to launch in the US during the forecast period. Other major drivers for the angina market are aging global population, enhanced survival after an MI, and rising prevalence of obesity, diabetes, and hypertension. Moreover, diagnosed cases of prinzmetal angina will grow at a CAGR of 16.5% during the forecast period which will directly benefit market expansion.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Projected to be Faced by the Market?
High cost of treatment to restrain product demand
High cost associated with the treatment and the regular uncertainty seen in reimbursement policies are the factors expected to restrict Prinzmetal Angina therapeutics market growth. Rise in concerns regarding side effects on the body is projected to challenge the Prinzmetal Angina market in the forecast period of 2023-2033.
On the other hand, non-adherence to cardiovascular medications has been observed among patients with cardiovascular diseases buying of generic medicines instead of specific branded drugs is anticipated to hamper market growth.
Region-Wise Insights
North America dominating the industry for Prinzmental Angina therapeutics
North America dominates the angina pectoris drugs market with a market share of around 42%, due to the established healthcare infrastructure, rising adoption of therapeutics, and the presence of key manufacturers in the United States, which is responsible for its large share. Ischemic heart disease is a major cause of death and disability within the North American region, while angina represents its most common symptom.
For instance, as per the data published by the National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, in February 2022, the most frequent type of heart disease, ischemic heart disease, claimed around 360,900 individual lives in 2020. Coronary artery disease affects approximately 18.2 million persons aged 20 and older. Adults under the age of 65 account for about 2 out of every 10 deaths due to coronary artery disease.
Similarly, an article titled "Ischemic Heart Disease: Noninvasive Imaging Techniques and Findings" published in RSNA (RadioGraphics), in May 2021, stated that in the United States alone, the annual incidence of new coronary events is around 720,000 instances, and the current prevalence of ischemic heart disease is around 18.3 million cases. Thus, such a higher prevalence of heart diseases is likely to increase the incidence of angina pectoris, thereby fueling demand for angina pectoris drugs within the region. Moreover, the rise in number of clinical trials is also fueling the market's growth. For instance, as of April 2022, there were 23 active and recruiting clinical trials for angina pectoris within the United States. Therefore, these factors together contribute to the expansion of angina pectoris drug market throughout the analysis period.
U.S. dominated the region by accounting for more than 40% of the market share in 2022. Established healthcare infrastructure, growing adoption of therapeutics, and presence of key manufacturers are responsible for its larger share. Also, rising incidence of cardiac disorders due to sedentary lifestyle and favorable regulatory initiatives are propelling market growth.
Changing regulatory scenario in the U.S. is expected to impact clinical trials of Advanced Therapy Medicinal Products. Multiple gene therapy products in Phase II/III trials are emerging as a novel approach towards addressing the need for non-surgical cardiovascular treatments. Taxus Cardium’s adenovector (serotype 5) DNA-based gene therapy is currently undergoing late-stage clinical trials and could present promising growth opportunities for the market in the forecast period.
South Asia to be fastest expanding market for Prinzmetal Angina therapeutics
South Asia is estimated to be the fastest growing region for the angina market owing to presence of developing economies such as India and China and a developing healthcare sector. This region is projected to witness growth with a CAGR of 4%. Increasing healthcare expenditure and favorable government policies are also anticipated to boost Angina Market growth during the forecast period.
China offers robust opportunities for market expansion due to removal of price caps on all medicine categories, the ongoing Healthy China 2020 healthcare reform, and supportive 12th Five-Year Plan measures that target biotechnology as key development sector. Furthermore, presence of a large target population and robust unmet clinical needs are some of the factors that are expected to fuel growth in this region.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category wise Insights
Beta blockers expected to dominate the segment by drug class
In patients with stable angina caused by CAD, beta-blockers are considered first-line therapy. The segment's growth is majorly attributed to an increase in target population and a rising number of strategic developments among market players for increasing the commercial availability of beta-blocker drugs.
For instance, in April 2022, New American Therapeutics provided Melinta Therapeutics the rights to TOPROL-XL (metoprolol succinate) in the United States. TOPROL-XL is a cardio-selective beta-blocker that has been approved by the FDA for the treatment of hypertension, either alone or in combination with other antihypertensives, as well as the long-term treatment of angina pectoris and the treatment of stable, symptomatic heart failure of specific causes. Such developments will strengthen the segment's growth in the forecast period.
Hospital Pharmacies expected to dominate the market by distribution channel
Hospital Pharmacies segment is projected to account for a segment share of 55% during the forecast period. This is mostly due to an increase in the number of patients with illnesses that require treatment in hospitals with modern infrastructure and suitable amenities. Furthermore, the expanding number of hospitals, as well as sufficient reimbursement rules, are both contributing to the segment's growth.
Start-ups in Prinzmetal Angina Therapeutics Market
- Founded in 2018, ‘Echopoint Medical’ is a London based developer of smart devices for monitoring coronary artery disease and microvascular dysfunction. The company is involved in the development of optical-fiber based sensors that integrate into medical devices for monitoring cardiac health. It has developed iKOs microcatheter device that uses nanomaterials and sensors that can be positioned into cardiovascular devices for detecting the heart conditions by using iKOR technology. Other products include IKOs imaging devices, iKOs 3D tracking devices, and more. It received a funding of USD 4 million from Parkwalk, UCL Technology Fund, Gov.uk and 1 Other Investors.
- Founded in 2015, ‘Angionetics’, a US-based start-up, is a subsidiary of Texas Cardium Pharmaceuticals Group. It is focused on the late-stage clinical development and commercialization of Generx, an angiogenic gene therapy for the treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. The Generx product candidate utilises a serotype 5 adenovirus (Ad5) to deliver the FGF-4 transgene into heart cells. The Generx product candidates are engineered to express FGF-4, a member of the fibroblast growth factor family.
- Founded in 2016, ‘Cleerly’ is a Provider of image-driven cardiac health assessment platform. It offers an AI-based diagnostic technology that characterizes and quantifies atherosclerotic plaque in the arteries based on coronary CT angiograms. It enables healthcare providers to diagnose, improves the health outcomes of employees, and provides personalized care. It was granted funding of USD 472 million from Fidelity Investments, T. Rowe Price, and 12 others.
Market Competition
Key players in the prinzmetal angina therapeutics market are: Sanofi S.A., Gilead Sciences; Inc., AstraZeneca Plc, Pfizer; Inc., Eli Lilly and Company, Amgen; Inc., GlaxoSmithKline Plc, Tasly Pharmaceuticals; Inc., Novartis AG, XyloCor Therapeutics
Some recent developments in this industry are:
- In March 2022, Zydus Lifesciences received approval from the United States Food and Drug Administration (FDA) to market its Nitroglycerin Sublingual Tablets in the strengths of 0.3 mg, 0.4mg, and 0.6mg (US RLD: Nitrostat Sublingual Tablets) for angina.
- In October 2021, BioCardia, Inc. announced the treatment of the patient in their CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with refractory angina.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 10.7 Billion |
|
Market Value in 2033 |
US$ 17.2 Billion |
|
Growth Rate |
CAGR of 4.85% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018-2022 |
|
Forecast Period |
2023-2033 |
|
Quantitative Units |
Revenue in US$ Billion and CAGR from 2023-2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Prinzmetal Angina Therapeutics Market Industry Survey
By Drug Class:
- Beta Blockers
- Calcium Antagonists
- Anti-coagulants
- Anti-Platelets
- Anti-Anginal
- ACE Inhibitors
- Nitrates
By Disease Type:
- Stable or Chronic Angina
- Unstable Angina
- Variant and Microvascular Angina
By Distribution Channel:
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
FMI projects the global prinzmetal angina therapeutics market to expand at a 4.85 % value CAGR by 2033.
The global prinzmetal angina therapeutics market is expected to garner a market value of US$ 17.2 billion by 2033.
FMI has projected North America to be one of the most profitable regions for the prinzmetal angina therapeutics market.
South Asia region is expected to grow fastest during the forecast period.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2018-2022
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2023-2033
5.3.1. Beta Blockers
5.3.2. Calcium Antagonists
5.3.3. Anti-coagulants
5.3.4. Anti-Platelets
5.3.5. Anti-Anginal
5.3.6. ACE inhibitors
5.3.7. Nitrates
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018-2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023-2033
6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Disease Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Disease Type, 2018-2022
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Type, 2023-2033
6.3.1. Stable or chronic angina
6.3.2. Unstable angina
6.3.3. Variant and microvascular angina
6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018-2022
6.5. Absolute $ Opportunity Analysis By Disease Type, 2023-2033
7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel , 2018-2022
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel , 2023-2033
7.3.1. Online pharmacies
7.3.2. Hospital pharmacies
7.3.3. Retail pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018-2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023-2033
8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Disease Type
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Disease Type
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Disease Type
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Disease Type
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Disease Type
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Disease Type
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Class
12.2.3. By Disease Type
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Disease Type
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Disease Type
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Disease Type
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018-2022 and Forecast 2023-2033, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Class
14.2.3. By Disease Type
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Disease Type
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country
15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Class
15.2.3. By Disease Type
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Disease Type
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. U.S.
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Class
16.1.2.2. By Disease Type
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Class
16.2.2.2. By Disease Type
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Class
16.3.2.2. By Disease Type
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Class
16.4.2.2. By Disease Type
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Class
16.5.2.2. By Disease Type
16.5.2.3. By Distribution Channel
16.6. U.K.
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Class
16.6.2.2. By Disease Type
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Class
16.7.2.2. By Disease Type
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Class
16.8.2.2. By Disease Type
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Class
16.9.2.2. By Disease Type
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Class
16.10.2.2. By Disease Type
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Class
16.11.2.2. By Disease Type
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Class
16.12.2.2. By Disease Type
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Class
16.13.2.2. By Disease Type
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Class
16.14.2.2. By Disease Type
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Class
16.15.2.2. By Disease Type
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Class
16.16.2.2. By Disease Type
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Class
16.17.2.2. By Disease Type
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Class
16.18.2.2. By Disease Type
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Class
16.19.2.2. By Disease Type
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Class
16.20.2.2. By Disease Type
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Class
16.21.2.2. By Disease Type
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By Disease Type
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Sanofi S.A.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Gilead Sciences; Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. AstraZeneca Plc
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Pfizer; Inc.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Eli Lilly and Company
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Amgen; Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. GlaxoSmithKline Plc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Tasly Pharmaceuticals; Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Novartis AG
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. XyloCor Therapeutics
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033
Table 2: Global Market Value (US$ Mn) Forecast by Drug Class, 2018-2033
Table 3: Global Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 4: Global Market Value (US$ Mn) Forecast by Distribution Channel , 2018-2033
Table 5: North America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 6: North America Market Value (US$ Mn) Forecast by Drug Class, 2018-2033
Table 7: North America Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 8: North America Market Value (US$ Mn) Forecast by Distribution Channel , 2018-2033
Table 9: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 10: Latin America Market Value (US$ Mn) Forecast by Drug Class, 2018-2033
Table 11: Latin America Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 12: Latin America Market Value (US$ Mn) Forecast by Distribution Channel , 2018-2033
Table 13: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 14: Europe Market Value (US$ Mn) Forecast by Drug Class, 2018-2033
Table 15: Europe Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 16: Europe Market Value (US$ Mn) Forecast by Distribution Channel , 2018-2033
Table 17: South Asia Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 18: South Asia Market Value (US$ Mn) Forecast by Drug Class, 2018-2033
Table 19: South Asia Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 20: South Asia Market Value (US$ Mn) Forecast by Distribution Channel , 2018-2033
Table 21: East Asia Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 22: East Asia Market Value (US$ Mn) Forecast by Drug Class, 2018-2033
Table 23: East Asia Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 24: East Asia Market Value (US$ Mn) Forecast by Distribution Channel , 2018-2033
Table 25: Oceania Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 26: Oceania Market Value (US$ Mn) Forecast by Drug Class, 2018-2033
Table 27: Oceania Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 28: Oceania Market Value (US$ Mn) Forecast by Distribution Channel , 2018-2033
Table 29: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 30: MEA Market Value (US$ Mn) Forecast by Drug Class, 2018-2033
Table 31: MEA Market Value (US$ Mn) Forecast by Disease Type, 2018-2033
Table 32: MEA Market Value (US$ Mn) Forecast by Distribution Channel , 2018-2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 2: Global Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 3: Global Market Value (US$ Mn) by Distribution Channel , 2023-2033
Figure 4: Global Market Value (US$ Mn) by Region, 2023-2033
Figure 5: Global Market Value (US$ Mn) Analysis by Region, 2018-2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033
Figure 8: Global Market Value (US$ Mn) Analysis by Drug Class, 2018-2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 11: Global Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 14: Global Market Value (US$ Mn) Analysis by Distribution Channel , 2018-2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023-2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023-2033
Figure 17: Global Market Attractiveness by Drug Class, 2023-2033
Figure 18: Global Market Attractiveness by Disease Type, 2023-2033
Figure 19: Global Market Attractiveness by Distribution Channel , 2023-2033
Figure 20: Global Market Attractiveness by Region, 2023-2033
Figure 21: North America Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 22: North America Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 23: North America Market Value (US$ Mn) by Distribution Channel , 2023-2033
Figure 24: North America Market Value (US$ Mn) by Country, 2023-2033
Figure 25: North America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 28: North America Market Value (US$ Mn) Analysis by Drug Class, 2018-2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 31: North America Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 34: North America Market Value (US$ Mn) Analysis by Distribution Channel , 2018-2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023-2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023-2033
Figure 37: North America Market Attractiveness by Drug Class, 2023-2033
Figure 38: North America Market Attractiveness by Disease Type, 2023-2033
Figure 39: North America Market Attractiveness by Distribution Channel , 2023-2033
Figure 40: North America Market Attractiveness by Country, 2023-2033
Figure 41: Latin America Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 42: Latin America Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 43: Latin America Market Value (US$ Mn) by Distribution Channel , 2023-2033
Figure 44: Latin America Market Value (US$ Mn) by Country, 2023-2033
Figure 45: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 48: Latin America Market Value (US$ Mn) Analysis by Drug Class, 2018-2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 51: Latin America Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 54: Latin America Market Value (US$ Mn) Analysis by Distribution Channel , 2018-2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023-2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023-2033
Figure 57: Latin America Market Attractiveness by Drug Class, 2023-2033
Figure 58: Latin America Market Attractiveness by Disease Type, 2023-2033
Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023-2033
Figure 60: Latin America Market Attractiveness by Country, 2023-2033
Figure 61: Europe Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 62: Europe Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 63: Europe Market Value (US$ Mn) by Distribution Channel , 2023-2033
Figure 64: Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 65: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 68: Europe Market Value (US$ Mn) Analysis by Drug Class, 2018-2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 71: Europe Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 74: Europe Market Value (US$ Mn) Analysis by Distribution Channel , 2018-2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023-2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023-2033
Figure 77: Europe Market Attractiveness by Drug Class, 2023-2033
Figure 78: Europe Market Attractiveness by Disease Type, 2023-2033
Figure 79: Europe Market Attractiveness by Distribution Channel , 2023-2033
Figure 80: Europe Market Attractiveness by Country, 2023-2033
Figure 81: South Asia Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 82: South Asia Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 83: South Asia Market Value (US$ Mn) by Distribution Channel , 2023-2033
Figure 84: South Asia Market Value (US$ Mn) by Country, 2023-2033
Figure 85: South Asia Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 88: South Asia Market Value (US$ Mn) Analysis by Drug Class, 2018-2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 91: South Asia Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 94: South Asia Market Value (US$ Mn) Analysis by Distribution Channel , 2018-2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023-2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023-2033
Figure 97: South Asia Market Attractiveness by Drug Class, 2023-2033
Figure 98: South Asia Market Attractiveness by Disease Type, 2023-2033
Figure 99: South Asia Market Attractiveness by Distribution Channel , 2023-2033
Figure 100: South Asia Market Attractiveness by Country, 2023-2033
Figure 101: East Asia Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 102: East Asia Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 103: East Asia Market Value (US$ Mn) by Distribution Channel , 2023-2033
Figure 104: East Asia Market Value (US$ Mn) by Country, 2023-2033
Figure 105: East Asia Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 108: East Asia Market Value (US$ Mn) Analysis by Drug Class, 2018-2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 111: East Asia Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 114: East Asia Market Value (US$ Mn) Analysis by Distribution Channel , 2018-2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023-2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023-2033
Figure 117: East Asia Market Attractiveness by Drug Class, 2023-2033
Figure 118: East Asia Market Attractiveness by Disease Type, 2023-2033
Figure 119: East Asia Market Attractiveness by Distribution Channel , 2023-2033
Figure 120: East Asia Market Attractiveness by Country, 2023-2033
Figure 121: Oceania Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 122: Oceania Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 123: Oceania Market Value (US$ Mn) by Distribution Channel , 2023-2033
Figure 124: Oceania Market Value (US$ Mn) by Country, 2023-2033
Figure 125: Oceania Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 128: Oceania Market Value (US$ Mn) Analysis by Drug Class, 2018-2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 131: Oceania Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 134: Oceania Market Value (US$ Mn) Analysis by Distribution Channel , 2018-2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel , 2023-2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023-2033
Figure 137: Oceania Market Attractiveness by Drug Class, 2023-2033
Figure 138: Oceania Market Attractiveness by Disease Type, 2023-2033
Figure 139: Oceania Market Attractiveness by Distribution Channel , 2023-2033
Figure 140: Oceania Market Attractiveness by Country, 2023-2033
Figure 141: MEA Market Value (US$ Mn) by Drug Class, 2023-2033
Figure 142: MEA Market Value (US$ Mn) by Disease Type, 2023-2033
Figure 143: MEA Market Value (US$ Mn) by Distribution Channel , 2023-2033
Figure 144: MEA Market Value (US$ Mn) by Country, 2023-2033
Figure 145: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 148: MEA Market Value (US$ Mn) Analysis by Drug Class, 2018-2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023-2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023-2033
Figure 151: MEA Market Value (US$ Mn) Analysis by Disease Type, 2018-2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033
Figure 154: MEA Market Value (US$ Mn) Analysis by Distribution Channel , 2018-2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023-2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023-2033
Figure 157: MEA Market Attractiveness by Drug Class, 2023-2033
Figure 158: MEA Market Attractiveness by Disease Type, 2023-2033
Figure 159: MEA Market Attractiveness by Distribution Channel , 2023-2033
Figure 160: MEA Market Attractiveness by Country, 2023-2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
